AtheroGenics (AGIX) Reports ARISE Phase III Clinical Study Doesn't Meet Enpoint
Tweet Send to a Friend
AtheroGenics, Inc. (Nasdaq: AGIX) announced that its ARISE Phase III clinical study of its lead drug candidate, AGI-1067, did not ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
